Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

AGM Statement

19 May 2016 07:00

RNS Number : 6672Y
Revolymer PLC
19 May 2016
 

19 May 2016

Revolymer plc ("Revolymer" or "the Company")

AGM Statement

At the Annual General Meeting of the Company being held today, Dr Bryan Dobson, Chairman of the Company will make the following comments:

"Trading in the first quarter of the current financial year is in line with our expectations, and we have continued to make good progress in gaining commercial traction with our product pipeline. In the Personal and Consumer Health Care market, our new line of natural hair styling polymers, RevCareTM Natural Effects, was well received at its product launch at the Paris InCosmetics trade show in April 2016. In the Home Care and Industrial market, RevCoatTM Bond, our novel polymeric adhesion promoter for high performance sealants and adhesives, is due for launch later in the second quarter of 2016. As announced on 25 January 2016, we have also secured a renewal and expansion of our contract to supply nicotine gum in Canada, as well as contracting with a new customer in Canada. 

This commercial progress follows on from our milestones in 2015, including two significant licence deals in our Home Care and Industrial business area (with Solvay and OCI). The Company is now positioned as a specialty chemicals business, focussed on controlled release, responsive systems and delivery systems that improve the functional performance of our customers' products in two high value business areas: Personal and Consumer Health Care and Home Care and Industrial, and we have aligned the organisation so that we are best placed to penetrate these markets.

Considering the remainder of 2016 and beyond, I look forward to continued commercial milestones being achieved in both our business areas, and management remains receptive to executing corporate transactions as a route to developing the business in parallel with its ongoing organic growth."

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Adam James / Fabien Holler (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

 

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) whose vision is to be a specialty chemicals business focused on controlled release, responsive systems and delivery systems based on its expertise in the design and synthesis of polymers that improve the functional performance of its customers' products, thereby generating high margin business.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMBCGDUUBBBGLI
Date   Source Headline
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar
8th Jun 20229:04 amRNSFinal Results - replacement
8th Jun 20227:30 amRNSTR-1
8th Jun 20227:00 amRNSFinal Results
6th Jun 20222:00 pmRNSPrice Monitoring Extension
27th May 20227:00 amRNSNotice of Final Results, Presentation and AGM
22nd Apr 20227:00 amRNSNew Funding to Support EU Volumes
20th Apr 20227:00 amRNSTrading Update
19th Apr 20227:00 amRNSBoard Changes
29th Mar 202211:05 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20224:35 pmRNSPrice Monitoring Extension
16th Feb 20224:41 pmRNSSecond Price Monitoring Extn
16th Feb 20224:36 pmRNSPrice Monitoring Extension
16th Feb 20227:00 amRNSInvestor Event
9th Feb 202211:06 amRNSSecond Price Monitoring Extn
9th Feb 202211:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.